While anti-VEGF therapies remain the current standard of care, many DME patients experience suboptimal responses due to ...

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

Zanzalintinib and atezolizumab improved overall survival in metastatic colorectal cancer compared to regorafenib, with a median OS of 10.9 vs 9.4 months. The combination showed progression-free ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...